Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025
Provided By GlobeNewswire
Last update: May 1, 2025
― Enrollment complete in the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); initiated the 20 mg dose cohort ―
― On track to provide clinical data from the 12 mg dose cohort in early Q3 2025 and the 20 mg dose cohort by the end of 2025 ―
Read more at globenewswire.comNASDAQ:FULC (8/25/2025, 12:59:22 PM)
6.6
-0.28 (-4.07%)
Find more stocks in the Stock Screener
